Article

HIFU yields 73% cancer-free rate at 6 months

Author(s):

Robert H. Carlson

Chicago-Treating localized prostate cancer with high-intensityfocused ultrasound (HIFU) appears to be safe, efficacious, and well tolerated,according to data presented by several European research groups at the AUAannual meeting in Chicago.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Shot of a doctor showing a patient some information on a digital tablet | Image Credit | © bongkarn - stock.adobe.com
OnabotA for OAB: Enhancing comfort and ensuring adherence
Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead
Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead
Navigating Access Barriers: Resources to Support New Treatment Access
Navigating Access Barriers: Resources to Support New Treatment Access
Overcoming Challenges in Accessing New Therapies for NMIBC
Overcoming Challenges in Accessing New Therapies for NMIBC
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
Maria Uloko, MD, on the need for better education on female sexual dysfunction
Maria Uloko, MD, on the need for better education on female sexual dysfunction
Dean Elterman, MD, on the shift toward personalized care in BPH
Dean Elterman, MD, on the shift toward personalized care in BPH
Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
Related Content
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
June 12th 2025

FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

Hannah Clarke
The approval is supported by findings from the phase 3 ENVISION trial.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
PSMA-PET imaging product, Gozellix, launches on US market
June 11th 2025

PSMA-PET imaging product, Gozellix, launches on US market

Hannah Clarke
Gozellix was approved by the FDA in March 2025.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Dipen Parekh, M.D. named Chief Executive Officer of the University of Miami Health System
June 11th 2025

Dipen Parekh, M.D. named Chief Executive Officer of the University of Miami Health System

University of Miami Health System Desai Sethi Urology Institute
Award-winning COO of UHealth, renowned surgeon scientist, and director of the Desai Sethi Urology Institute elevated to lead patient-focused care, biomedical research, and medical education
Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients
June 11th 2025

Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients

Cleveland Clinic
Glean™ Urodynamics System developed by Bright Uro based on foundational technology created at Cleveland Clinic; Device received FDA clearance earlier this year
© 2025 MJH Life Sciences

All rights reserved.